Castle

Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

Retrieved on: 
星期三, 五月 15, 2024
Science, Other Science, Biotechnology, Research, Oncology, Health, Genetics, Other Health, Webcast, Castle, Conference

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:00 p.m. Eastern time.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:00 p.m. Eastern time.
  • A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/ .
  • A replay of the webcast will be available following the conclusion of the live broadcast.

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Retrieved on: 
星期三, 四月 10, 2024
Oncology, Health, Genetics, Other Health, Other Science, Science, Biotechnology, Steps, Education, Risk, Esophageal cancer, ECAN, CPI, Research, Hepatology, GI, Disease, Patient, Physician, Northwestern University, Diagnosis, GERD, Castle, FACP, Division, Gastroesophageal reflux disease, FACG, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April.
  • The Company is proud to continue its ongoing collaboration with the Esophageal Cancer Action Network (ECAN), Gastro Broadcast podcast and EndoscopyNow to help advance esophageal cancer research, prevention, education and advocacy.
  • “Unfortunately, esophageal cancer is often detected at its late stages and the five-year survival rate of esophageal cancer patients is less than 20%,”1 said Emmanuel Gorospe, M.D., MPH, CPI, FACP, FACG, FASGE, GI Medical Director at Castle Biosciences.
  • TissueCypher® is Castle’s prognostic risk-stratification test designed to predict progression to high-grade dysplasia or esophageal cancer.

Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

Retrieved on: 
星期四, 四月 4, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Sentinel lymph node, SCC, Congress, Castle, Risk, Patient, Neoplasm, Research, NCCN, AJCC, National Comprehensive Cancer Network, Risk assessment, Lymph node, Carcinoma, Melanoma, Trial of the century, Recurrence, Metastasis, SLN, Medical imaging

Summary: The DecisionDx-Melanoma test has been validated to predict individual risk of SLNB positivity and five-year risk of recurrence and metastasis for patients with CM.

Key Points: 
  • Summary: The DecisionDx-Melanoma test has been validated to predict individual risk of SLNB positivity and five-year risk of recurrence and metastasis for patients with CM.
  • This study explored the cost-savings impact of using the DecisionDx-Melanoma test to guide risk-aligned clinical decision-making versus using the current melanoma staging standard, a patient’s AJCC stage.
  • Summary: The DecisionDx-SCC test uses a patient’s tumor biology to independently predict risk of regional or distant metastasis in patients with high-risk SCC.
  • These data demonstrate that DecisionDx-SCC improves the accuracy of risk assessment based solely on clinicopathological risk factors, leading to more appropriate risk-aligned management plans for patients with high-risk SCC.

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
星期二, 四月 2, 2024
Research, Medical Devices, Genetics, Health Technology, Other Health, Biotechnology, Health, Science, Oncology, Other Science, Webcast, Castle, Conference

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. Eastern time.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. Eastern time.
  • A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx .
  • A replay of the webcast will be available following the conclusion of the live broadcast.

Williams Homes, Inc. Announces Internal Promotions of Seven Key Executive Leadership Posts

Retrieved on: 
星期四, 三月 14, 2024
Construction & Property, Residential Building & Real Estate, David Seidner, Castle, Marketing, Home, Faina, Pardee Homes, Management

“These gentlemen are genuine attributes to our executive management team,” said Lance Williams, Williams Homes’ chairman and CEO.

Key Points: 
  • “These gentlemen are genuine attributes to our executive management team,” said Lance Williams, Williams Homes’ chairman and CEO.
  • “As the company continues to grow, we are only as good as the vision, work ethic and leadership of those around us.
  • Milano has been promoted to division president, Southern California after joining Williams Homes in 2021 and serving as vice president of land acquisitions.
  • Von Quilich will serve as interim division president, Texas while maintaining his existing role as division president, Northern California.

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Retrieved on: 
星期二, 三月 12, 2024
Medical Supplies, Biotechnology, Health, Pharmaceutical, Oncology, Mental Health, Health Technology, Other Science, Medical Devices, Genetics, Science, Webcast, Castle, Medtech

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 11:15 a.m. Eastern time.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 11:15 a.m. Eastern time.
  • A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx .
  • A replay of the webcast will be available following the conclusion of the live broadcast.

IMG Saxony-Anhalt presents its new tourism offers at ITB Berlin 2024 - a plus in overnight stays by foreign guests

Retrieved on: 
星期三, 三月 20, 2024
Citadel, Saale-Unstrut, Castle, Magdeburg Cathedral, Harz, ITB, IMG, Reformation, Bauhaus Museum, Travel, Brocken Railway, News, Iron, German National Tourist Board, UNESCO, Marketing, City, Investment, Tourism, Naumburg Cathedral, Iron Curtain, Culture, Bauhaus Dessau, GNTB, All Saints' Church, Wittenberg

According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.

Key Points: 
  • According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.
  • This corresponds to an increase of seven percent in guest arrivals and six percent in overnight stays compared to the previous year.
  • Also, eleven percent more international guests came to Saxony-Anhalt with over a quarter of a million arrivals, which clearly exceeds the pre-Corona level.
  • This good news and the new offers "Hello, Saxony-Anhalt" were presented at the joint booth of the German National Tourist Board (GNTB) at the ITB 2024.

IMG Saxony-Anhalt presents its new tourism offers at ITB Berlin 2024 - a plus in overnight stays by foreign guests

Retrieved on: 
星期一, 三月 18, 2024
Citadel, Saale-Unstrut, Castle, Magdeburg Cathedral, Harz, ITB, IMG, Reformation, Bauhaus Museum, Travel, Brocken Railway, News, Iron, German National Tourist Board, UNESCO, Marketing, City, Investment, Tourism, Naumburg Cathedral, Iron Curtain, Culture, Bauhaus Dessau, GNTB, All Saints' Church, Wittenberg

According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.

Key Points: 
  • According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.
  • This corresponds to an increase of seven percent in guest arrivals and six percent in overnight stays compared to the previous year.
  • Also, eleven percent more international guests came to Saxony-Anhalt with over a quarter of a million arrivals, which clearly exceeds the pre-Corona level.
  • This good news and the new offers "Hello, Saxony-Anhalt" were presented at the joint booth of the German National Tourist Board (GNTB) at the ITB 2024.

IMG Saxony-Anhalt presents its new tourism offers at ITB Berlin 2024 - a plus in overnight stays by foreign guests

Retrieved on: 
星期一, 三月 18, 2024
Citadel, Saale-Unstrut, Castle, Magdeburg Cathedral, Harz, ITB, IMG, Reformation, Bauhaus Museum, Travel, Brocken Railway, News, Iron, German National Tourist Board, UNESCO, Marketing, City, Investment, Tourism, Naumburg Cathedral, Iron Curtain, Culture, Bauhaus Dessau, GNTB, All Saints' Church, Wittenberg

According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.

Key Points: 
  • According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.
  • This corresponds to an increase of seven percent in guest arrivals and six percent in overnight stays compared to the previous year.
  • Also, eleven percent more international guests came to Saxony-Anhalt with over a quarter of a million arrivals, which clearly exceeds the pre-Corona level.
  • This good news and the new offers "Hello, Saxony-Anhalt" were presented at the joint booth of the German National Tourist Board (GNTB) at the ITB 2024.

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
星期五, 三月 8, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, JAAD, Risk, Annual general meeting, AAD, Skin, Abstract, Patient, Castle, GEP, Dermatology, American Academy, Pharmaceutical industry

In the study, use of the DecisionDx-Melanoma test was associated with improved melanoma-specific survival relative to untested patients.

Key Points: 
  • In the study, use of the DecisionDx-Melanoma test was associated with improved melanoma-specific survival relative to untested patients.
  • The study data demonstrate that clinicians are utilizing the DecisionDx-SCC test appropriately for patients with high-risk cutaneous squamous cell carcinoma (SCC).
  • These data support incorporating the test’s results into clinical practice to improve the accuracy of risk predictions to guide more personalized treatment plans for patients.
  • Approximately 80% of clinically tested lesions with a malignant MyPath result have sufficient biopsy tumor content for DecisionDx-Melanoma testing.